New York, NY – July 11, 2016 – Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), in the Company’s uplisting to the NASDAQ Capital Market. The Sichenzia Ross Friedman Ference LLP team was led by partners Gregory Sichenzia and David Manno.
The uplisting is effective for trading on July 12, 2016 and DelMar’s common stock will trade under its existing stock symbol: “DMPI”. We are pleased to announce that Partners Gregory Sichenzia and David Manno and Counsel Jeffrey Cahlon will Join Delmar Pharmaceuticals in ringing NASDAQ’S Opening Bell on July 14, 2016. Join us and watch live on CNBC: 9:30am EST – Visit here to learn more about the NASDAQ Opening Bell
Founding Partner Gregory Sichenzia stated: “We congratulate DelMar Pharmaceuticals, Inc. on this terrific achievement and look forward to continuing to represent them as they achieve more milestones.”
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerant to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
[starbox id=1]
